Millions with gluten intolerance—triggered by this protein in wheat, oats, rye, barley, Kamut, and spelt—stand to benefit from a breakthrough study published in The American Journal of Gastroenterology. Researchers outline a potential new approach to managing celiac disease.
Celiac disease erodes the small intestine's lining, hindering gluten digestion and sparking inflammation. Canadian researchers from the University of Ontario pinpointed a key factor: the enzyme tissue transglutaminase 2, isolated from patients, drives inflammation. Crucially, those affected have far fewer Elafin molecules than healthy individuals. Elafin safeguards and repairs the damaged intestinal mucosa against gluten.
These insights proved effective in mouse studies: Elafin injections fully protected the gut lining.
Study researcher Elena Verdu emphasizes that while Elafin injections won't cure celiac disease outright, they could enhance daily life by healing intestinal connections, allowing better symptom management. Patients would still need caution but greater dietary flexibility.
